AcouSort AB (ACOU) AI Stock Analysis

• Market Cap: kr48.04M
• Dividend Yield: N/A
• Average Volume (3M): 29.24K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.42
• Revenue Growth: 59.70%
• EPS Growth: 44.60%
• Country: SE
• Employees: 17
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.13
• Shares Outstanding: 21,163,902
• 10 Day Avg. Volume: 27,764
• 30 Day Avg. Volume: 29,240
• PEG Ratio: 0.50
• Price to Book (P/B): 19.41
• Price to Sales (P/S): 34.67
• P/FCF Ratio: -8.28
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: kr2.00 ▼(-24.24% Downside)

The score is held down primarily by persistent losses and significant negative cash flow despite strong recent revenue growth, which increases financing/dilution risk. Technicals add only modest support with short-term strength but a longer-term downtrend and negative MACD. Valuation is also constrained by a negative P/E and no stated dividend yield.

Positive Factors

Debt-free balance sheet

A zero-debt capital structure materially reduces refinancing risk and interest obligations, giving management flexibility to allocate existing capital toward R&D, commercialization and pilot programs. Over a 2–6 month horizon this improves resilience while the company scales.

Strong recent revenue rebound

A ~+90% TTM revenue rebound signals improving commercial traction and demand validation for the product suite. Sustained top-line growth supports scaling of operations and can help spread fixed costs, improving odds of moving toward positive operating leverage.

Proprietary acoustofluidic platform

A differentiated, label-free acoustic sorting platform addresses structural growth in cell therapy and bioprocessing. Durable competitive advantage comes from specialized tech fit for continuous-flow manufacturing, increasing likelihood of sustained customer demand as the industry matures.

Negative Factors

High cash burn

Persistent -€16–17M operating/free cash flow indicates material cash burn that will require external financing or strong margin improvement to sustain growth. Over months, burn constrains hiring, commercialization and pilot expansion until cash flow turns positive or funding is secured.

Weak margins and large operating losses

A ~16% gross margin combined with an ~-217% EBIT margin reflects structural profitability challenges. Low gross margins limit the company's ability to self-fund growth and mean achieving sustainable profits will require either substantial margin expansion or much higher recurring revenue levels.

Negative returns and dilution risk

Deeply negative ROE (~-93%) and ongoing losses erode equity and raise the probability of additional capital raises. Over a 2–6 month horizon, this increases shareholder dilution risk and may shift management focus from execution to securing funding.

AcouSort AB Business Overview & Revenue Model

Company Description

AcouSort AB (publ), a technology company, develops products and solutions for automated preparation of biological samples based on acoustofluidics technology for researchers and life science companies. It offers AcouTrap, a benchtop research instrument for sample preparation of cells, extracellular vesicles, bacteria, and viruses from various media; AcouPlasma, an integrated blood plasma separation module that enables in-line analysis of blood plasma from whole blood samples; and AcouWash, a benchtop research instrument for label-free separation of target cells from various samples. The company was founded in 2010 and is based in Lund, Sweden.

How the Company Makes Money

AcouSort AB generates revenue through the sale of its acoustic separation systems and devices to research institutions, diagnostic companies, and clinical laboratories. The company also earns income by providing custom solutions and services that leverage its proprietary technology for specific customer needs. Additionally, AcouSort may engage in partnerships and collaborations with other companies and research entities to further develop and market its technologies, which can also contribute to its revenue streams through licensing agreements or joint ventures. The company's earnings are influenced by the demand for advanced diagnostic and research tools that can offer improved efficiency and accuracy in biological sample processing.

AcouSort AB Financial Statement Overview

Summary

Revenue rebounded strongly in the TTM period (~+90%), and the company is debt-free, reducing balance-sheet risk. However, profitability and cash generation are weak: low gross margin (~16%), very large operating losses (EBIT margin ~-217%), deeply negative ROE (~-93%), and materially negative operating/free cash flow (about -16 to -17M) indicate ongoing cash burn and funding dependence.

Income Statement

TTM (Trailing-Twelve-Months) revenue rebounded strongly (about +90% growth), but profitability remains weak: gross margin is low (~16%) and operating losses are large (EBIT margin around -217%), resulting in a deeply negative net margin. Over the past several annual periods, revenue has been volatile (sharp declines and rebounds), while losses have persisted, indicating the business has not yet reached a stable, scalable earnings profile.

Balance Sheet

The balance sheet is supported by a debt-free capital structure (total debt at 0; debt-to-equity at 0), which reduces financial risk and refinancing pressure. However, returns remain very negative (TTM return on equity roughly -93%), reflecting ongoing losses that can continue to erode equity over time if not reversed.

Cash Flow

Cash generation is a key weakness: TTM (Trailing-Twelve-Months) operating cash flow and free cash flow are both significantly negative (around -16 to -17 million), and free cash flow deterioration versus the prior period is steep. While free cash flow has generally tracked net losses (free cash flow roughly in line with net income in multiple periods), the company remains in cash-burn mode, increasing funding dependence if losses persist.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	5.62M	4.74M	10.55M	4.96M	3.01M	4.93M
Gross Profit	880.00K	4.77M	8.39M	2.91M	548.00K	3.04M
EBITDA	-11.98M	-15.89M	-16.70M	-12.86M	-11.46M	-7.64M
Net Income	-12.36M	-15.08M	-17.09M	-13.21M	-12.38M	-8.22M
Balance Sheet
Total Assets	21.86M	12.32M	34.51M	42.66M	36.56M	13.17M
Cash, Cash Equivalents and Short-Term Investments	11.83M	3.57M	23.99M	33.97M	31.52M	8.12M
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	3.21M	3.86M	10.38M	22.54M	3.54M	3.58M
Stockholders Equity	18.65M	8.46M	24.14M	20.11M	33.02M	9.59M
Cash Flow
Free Cash Flow	-16.96M	-19.84M	-31.77M	2.95M	-12.23M	-8.63M
Operating Cash Flow	-16.42M	-18.81M	-31.56M	3.96M	-10.92M	-7.04M
Investing Cash Flow	503.00K	-1.02M	-1.16M	-1.01M	-1.31M	-1.59M
Financing Cash Flow	18.87M	-157.00K	22.08M	0.00	35.63M	11.65M

AcouSort AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.64
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ACOU, the sentiment is Negative. The current price of 2.64 is below the 20-day moving average (MA) of 2.67, below the 50-day MA of 2.69, and below the 200-day MA of 3.10, indicating a bearish trend. The MACD of -0.12 indicates Positive momentum. The RSI at 33.42 is Neutral, neither overbought nor oversold. The STOCH value of 5.91 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ACOU.

AcouSort AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SPRINT	49 Neutral	kr175.68M	-5.31	-264.12%	―	-17.80%	-11.96%
ACOU	46 Neutral	kr48.04M	-2.93	-80.90%	―	59.70%	44.60%
PILA	45 Neutral	kr47.72M	-3.08	-601.02%	―	―	―
EXPRS2	45 Neutral	kr58.60M	-0.81	-88.65%	―	8.46%	11.73%
LARK	43 Neutral	kr42.57M	-0.96	―	8.47%	-94.12%	-25.83%
ONCOZ	41 Neutral	kr71.33M	-8.49	-78.79%	―	―	20.55%